Rampart Bioscience
Louis Breton is an accomplished biotechnology executive with extensive leadership experience in various companies. Currently serving as CEO and Co-Founder of Rampart Bioscience since January 2020, Louis has previously held CEO roles at ARC Technologies Consulting and Calimmune, Inc. (acquired by CSL). Louis co-founded CellzDirect, Inc. and served as its CEO until its acquisition by Invitrogen. Earlier in career, Louis contributed to business development as a founding member at ICS and led Breton International Consulting as Owner/President before its acquisition. Louis has also held roles in marketing and business coaching, as well as academic positions including Assistant Professor at the University of Arizona. Educational background includes a Bachelor's Degree in Molecular and Cellular Biology from the University of Arizona and studies at the University of Pennsylvania and the Keck School of Medicine of the University of Southern California.
This person is not in any teams
This person is not in any offices
Rampart Bioscience
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies. Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.